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Abstract. 
The modelling pharmacokinetic profile of freeze-dried cyclosporine A-Eudragit S100 nanoparticles 
(CyA-S100-NP was studied with a random two-way crossover study in dogs. The drug blood 
concentration was determined by internal standard HPLC method after oral administration of 
CyA-S100-NP and Neoral. Pharmacokinetics modellng parameters were calculated by  
3P97modelling program. The concentration-time data were fitted as a two-compartment open model. 
The AUC of CyA-S100-NP was higher than that of Neoral P 0.05 , while the CL significantly 
decreased P 0.05 . The relative bioavailability of CyA-S100-NP were 135.9% compared with 
Neoral. The bioavailability of CyA was significantly improved. CyA-S100-NP was a potential drug 
for developing a new CyA nanoparticles solid formulation. 
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1.Introduction  
Cyclosporine A (CyA), an immunosuppressant, has been used for preventing organ transplant rejection 
in humans and the treatment of systemic and local autoimmune disorders. However, it is known that the 
oral bioavailability of CyA is usually very low with a high inter- and intra-patient variability due to the 
poor absorption, which is related to the relatively high molecular weight, very high lipophilicity and 
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extensive metabolism. Moreover, the major limitation of CyA remains hepatotoxicity, nephrotoxicity, 
central nervous system toxicity and gastroenteric reaction ( Cohen et al., 1984; Thomson et al., 1991; Tjai 
et al., 1991).Most studies have been performed to decrease the above mentioned side effects and increase 
the therapeutic efficacy of CyA. CyA-nanoparticles have been used extensively as a formulation for 
improving the bioavailability of poorly water-soluble drugs due to its small particle size and unique 
uptake mechanisms. In addition, smaller particles are more readily absorbed (Hillyer et al., 2001). By 
virtue of enterically soluble polymers (Eudragits® S100 ), which can dissolve at specific pH values, 
cyclosporin A pH sensitive nanoparticles could target different parts of the gastrointestinal tract and 
protect metabolism of the incorporated drug, meanwhile, not containing Cremophor RH40. Cremophor 
RH40 exert nephrotoxic and may cause anaphylactoid reactions (Luke et al., 1987). It has been reported 
that pH-sensitive nanoparticles improved the absorption and bioavailability of CyA. (Dai et al., 2004; 
Wang et al., 2004).Yang et al. demonstrated CyA-Eudragit S100-Nanoparticles significantly improved 
the bioavailability of CyA after oral administration to rats (YANG et al., 2008). The pharmacokinetics of 
CyA have been investigated extensively in the dogs (Ford et al., 1999; Lee et al., 2001; El-Shabouri et al., 
2002), as this species has been used as the model for organ transplantation in humans. Moreover, the 
pharmacokinetics and metabolic patten are similar in dogs and humans (Venkataramanan et al., 1988; 
Vickers et al., 1992). The bioavailability and pharmacokinetics of CyA from these nanoparticles in 
comparison with the commercial microemulsion formulation (Sandimmune® Neoral) were assessed in 
dogs. 
2. Methods 
2.1. Preparation of CyA-S100-NP capsules  Anhydrous ethanol containing CyA/Eudragit® S100 
(1:4, w/w) were injected as soon as possible into stirring water containing 125 mg Poloxamer 188 at room 
temperature (organic phase/aqueous phase, 2:5 ). The mixture was stirred at 400 rpm, 10 min later, 
ethanol residues were left to evaporate in a 60  water bath for 3 h and then CyA-S100-NP colloids were 
obtained. The CyA-NP was concentrated to 8 mg CyA per milliliter before applied. Aliquots (3 mL)  
were placed in sealed vials in the presence of 2.5% lactose and frozen at -70  for 24 h. Then, the 
samples were immediately placed on the shelves of the freeze- drying chamber (ALPHA 1-4/LD, Marin 
Christ Co., Germany). Sublimation lasted 28 h without heating. Finally, CyA-S100-NP capsules were 
obtained (ZHANG et al., 2008). 
2.2. Particle Size Analysis   CyA-S100-NP were diluted 10-fold by ultrapure water, prior to 
examination. The analysis of particle size was performed by dynamic light scattering (Malvern 
Instruments Ltd, UK) at the wavelength of 670 nm and the temperature of 25  .  
2.3. Drug Loading and Encapsulation Efficiency   Prepared suspension of CyA-NP was filtered 
through a 0.45 m filter to remove insoluble polymer residues and CyA microcrystals. Then, 8 ml of the 
filtered suspension was ultracentrifuged at 250, 000 × g for 60 min under 10  and the supernatant was 
sampled (YANG et al., 2008). CyA content in the filtered suspension and in the supernatant were 
analyzed by HPLC. The HPLC system is composed of two pumps (LC-20AD, Shimadzu, Japan), UV-vis 
detector set at 210 nm. The chromatographic column used was BDS HYPERSIL C18 (5 m in 4.6 
mm×250 mm, Thermo Fisher Scientific, USA) maintained at 70 . The mobile phase consisted of  
acetonitrile/(methanol: water) {55/45 (1:1) ,v/v} and the flow rate was 1.3 ml/min-1. The injection volume 
was 20 ml. The yield, encapsulation efficiency (EP%) and drug loading efficiency (LD%) were 
calculated..  
2.4. Sample Preparation CyA in blood was determined by a reversed phase HPLC method, as 
mentioned above. Briefly, 0.5 ml of blood sample was added to a centrifuge tube, then 50 l of internal 
standard (cyclosporine D, CyD) in methanol at a concentration of 30 g·mL-l and 1 ml of hydrochloric 
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acid (180 mmol·L-l) were added. After vortex mixing for 1 min, 5 ml of ether was added. The extraction 
was carried out by shaking the tube horizontally for 15 min at 100 rpm, centrifuging it for 15 min at 4000 
rpm, and separating the ether phase to another centrifuge tube. After 1 ml of sodium hydroxide solution 
(95 mmol·L-l) and 2.5 ml of 1% sodium pyrosulfite solution were added, the extraction was repeated by 
the same procedure as described above. The ether layer was transferred into a clean tube and evaporated 
to dryness under nitrogen at 40 . The residue was reconstituted with 150 l of acetonitrile/water (70/30, 
v/v). The reconstituted blood samples were washed three times by 1 ml of n-hexane (LI et al., 1999). 20 
L of residual solution was injected into the HPLC system for the determination of CyA and CyD.  
2.5. Method validation   50 L CyA methanol solution with concentrations of 0.5025 1.005
5.025 10.05 20.1 30.15 g·mL-1 was added to 0.5 ml blank whole blood giving final concentrations 
of 0.05025 0.1005 0.5025 1.005 2.01 3.015 g·mL-1, in the presence of internal standard CyD 
(30 g·mL-1). Each blood standard was then treated with the same preparation procedure described above. 
Quantitation was done by determination of peak-area ratio of CyA/CyD (A/Ai) against the drug 
concentrations. The concentrations of unknown samples were determined by using the linear regression 
line of the concentration of the calibration standard versus peak-area ratios.50 L CyA methanol solution 
with concentrations of 0.5025 1.005 2.01 g·mL-1 was added to 0.5 ml blank whole blood, then each 
blood standard was taken through the sample preparation procedure described above. 20 L residual 
solution was injected into the HPLC system to calculate the recovery of CyA. Five times one day, and 
repeated for 5 days to estimate intra-day and inter-day precision. 
2.6. Experimental Design  Six healthy dogs were randomly divided into three groups. 
CyA-S100-NP and Neoral (equivalent to 10 mg·kg-1 of CyA) were orally administered to dogs in each 
group, respectively. The dogs were fasted overnight prior to the experiments and continued for further 4 h 
after administration, but allowed free access to water. The washout period was two weeks. At 
predetermined time intervals (0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 36 h), blood samples (1 ml) were drawn 
from the antecubital vein into heparinized tubes and stored in the frozen state for subsequent  analysis. 
2.7. Statistical Analysis  Pharmacokinetic parameters were estimated using 3P97 (a computer 
program produced by the Committee of Mathematical Pharmacology of the Chinese Society of 
Pharmacology). The maximal concentration (Cmax) and the time to maximal concentration (tmax) were 
obtained directly by observation. The total area under the concentration-time curve (AUC) from time zero 
to infinity was calculated by the trapezoidal rule method. The statistical and graphical analyses were 
accomplished using commonly available commercial software packages. Differences between the mean 
values were analyzed by multiple comparison test where P 0.05 was considered to be significance. All 
results were expressed as mean±standard deviation. 
3. Results  
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3.1 Characterization of CyA-S100-NP  The mean particle size of CyA-S100-NP was 52.7±4.6nm. 
CyA-S100-NP had a loading efficiency of 22.9±0.2% and displayed high encapsulation efficiency over 
99.5%. The yield was 98.1±0.2%  
3.2 Linearity  Under the described chromatographic conditions, CyD can be separated from CyA. As 
Fig 1 shown, There was no endogenous substance in the blood which would interfere with the 
determination of CyA and CyD, and there was no impurity introduced in the sample preparation 
procedure. The linearity of CyA was determined in the range 0.05025-3.015 g·mL-1 with a regression 
coefficient of 0.9994. The regression equation of concentration of CyA in the blood: C = 2.5098Ai
0.1044. 
 
Fig 1  HPLC chromatograms of CyA in blood. A blank blood B blank blood containing CyA and CyD D C blood sample 1 
CyA 2 CyD 
3.3 Recovery and Precision   The mean extract recovery rate of CyA was over 94% and the method 
recovery rate was 94.1%-102.7%, the intra-day and inter-day precision were less than 10% (Table 1). 
While the recovery rate of CyD was 96.58±6.563%.  
Table 1 The recovery and precision of CyA in blood ( x ±S) 
Added 
concentration 
( g·mL-1) 
Recovery (%) RSD (%) 
Extract Method Intra-day Inter-day
0.5025 94.92±8.522 102.7±6.267 6.103 9.083 
1.005 104.9±8.402 94.12±1.942 2.063 4.544 
2.010 109.1±2.868 95.43±2.575 2.698 4.640 
3.4 Pharmacokinetics  The blood concentration profile of CyA in dogs after oral administration of a 
10mg·kg-1 dose is presented in Fig.2. A two-compartment open model was adequate to describe the blood 
pharmacokinetics of CyA in dogs. The data obtained from the individual dogs were analysed by the two 
compartment model, using 3P97 software for final parameter estimates. Corresponding pharmacokinetic 
parameters are listed in Table 2. 
 
Fig.2 The mean blood concentration-time curve of CyA following oral administration of CyA-S100-NP and Neoral to dogs (n=6) 
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Table 2  Pharmacokinetic parameters of CyA after a single oral dose of Neoral and CyA-S100-NP ( x ±S)  
Parameters Neoral CyA-S100-NP 
AUC0-36h g·mL-1·h 10.66 ±2.01 14.49 ±3.00
* 
AUC0- h g·mL-1·h 12.77 ±3.08 17.08 ±2.66
* 
Cmax g·mL-1) 1.08 ±0.07 1.38 ±0.22
* 
Tmax h  2.17 ±0.93 2.25 ±0.88 
MRT h  10.94 ±0.94 11.16 ±0.97 
V/F(c) L·kg-1  4.76 ±0.98 5.40 ±0.47 
CL L·h-1  0.80 ±0.20 0.57 ±0.09* 
Fr %  —— 135.9 
Relative bioavailability: Fr % = (AUCtest×DNeoral /AUCNeoral×Dtest)×100%   P 0.05 vs.Neoral 
The results obtained revealed that the Cmax and AUC of  CyA from CyA-S100-NP show significant 
difference (P 0.05) when compared with those of Neoral. The relative bioavailability CyA-S100-NP to 
the reference was 135.9%. In addition, the CL was decreased significantly (P 0.05). There were no 
significant differences in other pharmacokinetic parameters of CyA between two formulations. 
4. Discussion  
Methodological approaches to determining the concentration of CyA in whole blood include high 
performance liquid chromatography (HPLC) and a variety of immunoassay-based methods, such as 
radioactive immunoassay (RIA), fluorescence polarization immunoassay (FPIA). Although 
immunoassay-based methods are simple to use, the cross-reactivity of the antibody with the metabolites 
leads to overestimation of CyA concentrations in blood by these methods. The HPLC method described 
here is specific, sensitive, reproducible and is applicable to pharmacokinetic studies of CyA. 
The treatment of blood samples of CyA include liquid-liquid extraction and solid-phase extraction 
method. The liquid-liquid extraction method is accurate and reproducible, although complicated. In this 
paper, the treatment of whole blood samples was established based on the study of LI et al. (LI et al., 
1999) including acidification, extraction, alkalization, washing and other steps. During the experiment, 
the amout of N-hexane and frequency of washing played a key role in removal of impurity. Under 
chromatographic conditions mentioned above, CyD could be separated from CyA. The results showed 
that accuracy and recovery were consistent with the determination of biological samples. This method is 
applicable to analysis of CyA concentration in dogs, and also to pharmacokinetic and bioavailability 
study in other species.   
The pharmacokinetics of CyA-S100-NP in dogs shows, the bioavailability of CyA was significantly 
improved. The Cmax and AUC from CyA-S100-NP were significantly increased as comparision of those 
from Neoral, while CL decreased significantly (P 0.05). The release profiles of cyclosporin A pH 
sensitive nanoparticles exhibit significant pH-sensitivity, there was a burst release of CyA from 
nanoparticles at specific part of the gastrointestinal tract (YANG et al., 2008), which is possible to 
decrease metabolism of the drug by gastrointestinal enzymes, increasing the oral bioavailability of CyA. 
Due to not only high oral bioavailability, but also long term stability, CyA-S100-NP could be a more 
effective nanoparticle solid formulation for oral delivery of poorly water-soluble CyA. 
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